Literature DB >> 12376327

Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice.

Kevin W Huggins1, Amy C Boileau, David Y Hui.   

Abstract

Group 1B phospholipase A2 (PLA2) is an abundant lipolytic enzyme that is well characterized biochemically and structurally. Because of its high level of expression in the pancreas, it has been presumed that PLA2 plays a role in the digestion of dietary lipids, but in vivo data have been lacking to support this theory. Our initial study on mice lacking PLA2 demonstrated no abnormalities in dietary lipid absorption in mice consuming a chow diet. However, the effects of PLA2 deficiency on animals consuming a high-fat diet have not been studied. To investigate this, PLA2(+/+) and PLA2(-/-) mice were fed a western diet for 16 wk. The results showed that PLA2(-/-) mice were resistant to high-fat diet-induced obesity. This observed weight difference was due to decreased adiposity present in the PLA2(-/-) mice. Compared with PLA2(+/+) mice, the PLA2(-/-) mice had 60% lower plasma insulin and 72% lower plasma leptin levels after high-fat diet feeding. The PLA2(-/-) mice also did not exhibit impaired glucose tolerance associated with the development of obesity-related insulin resistance as observed in the PLA2(+/+) mice. To investigate the mechanism by which PLA(2)(-/-) mice exhibit decreased weight gain while on a high-fat diet, fat absorption studies were performed. The PLA(2)(-/-) mice displayed 50 and 35% decreased plasma [(3)H]triglyceride concentrations 4 and 6 h, respectively, after feeding on a lipid-rich meal containing [(3)H]triolein. The PLA(2)(-/-) mice also displayed increased lipid content in the stool, thus indicating decreased fat absorption in these animals. These results suggest a novel role for PLA(2) in the protection against diet-induced obesity and obesity-related insulin resistance, thereby offering a new target for treatment of obesity and diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376327     DOI: 10.1152/ajpendo.00110.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  42 in total

1.  Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.

Authors:  Mohamad Navab; Arnab Chattopadhyay; Greg Hough; David Meriwether; Spencer I Fogelman; Alan C Wagner; Victor Grijalva; Feng Su; G M Anantharamaiah; Lin H Hwang; Kym F Faull; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2015-02-02       Impact factor: 5.922

2.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

3.  The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice.

Authors:  D Y Hui; M J Cope; E D Labonté; H-T Chang; J Shao; E Goka; A Abousalham; D Charmot; J Buysse
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 4.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

Review 5.  GutSelf: Interindividual Variability in the Processing of Dietary Compounds by the Human Gastrointestinal Tract.

Authors:  Barbara Walther; Aaron M Lett; Alessandra Bordoni; Lidia Tomás-Cobos; Juan Antonio Nieto; Didier Dupont; Francesca Danesi; Danit R Shahar; Ana Echaniz; Roberta Re; Aida Sainz Fernandez; Amélie Deglaire; Doreen Gille; Alexandra Schmid; Guy Vergères
Journal:  Mol Nutr Food Res       Date:  2019-10-01       Impact factor: 5.914

6.  Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.

Authors:  Eric D Labonté; Paul T Pfluger; James G Cash; David G Kuhel; Juan C Roja; Daniel P Magness; Ronald J Jandacek; Matthias H Tschöp; David Y Hui
Journal:  FASEB J       Date:  2010-03-09       Impact factor: 5.191

Review 7.  The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD).

Authors:  Aybike Birerdinc; Sasha Stoddard; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2018-04-19

8.  Structural insight into the activation mechanism of human pancreatic prophospholipase A2.

Authors:  Wei Xu; Lina Yi; Yumei Feng; Ling Chen; Jinsong Liu
Journal:  J Biol Chem       Date:  2009-03-18       Impact factor: 5.157

9.  A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung.

Authors:  Intae Lee; Chandra Dodia; Shampa Chatterjee; John Zagorski; Clementina Mesaros; Ian A Blair; Sheldon I Feinstein; Mahendra Jain; Aron B Fisher
Journal:  J Pharmacol Exp Ther       Date:  2013-03-08       Impact factor: 4.030

10.  Glucose homeostasis, insulin secretion, and islet phospholipids in mice that overexpress iPLA2beta in pancreatic beta-cells and in iPLA2beta-null mice.

Authors:  Shunzhong Bao; David A Jacobson; Mary Wohltmann; Alan Bohrer; Wu Jin; Louis H Philipson; John Turk
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-25       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.